Prostate Intelligence™

Lucida Medical

Prostate Intelligence software intended to assist analysis of MRI for suspected prostate cancer. It uses a combination of image processing, deep learning and machine learning methods, to segment the prostate, identify regions of interest, and calculate risk scores.
Product specifications Information source: Vendor
Last updated: Oct. 26, 2023
Product name Prostate Intelligence™
Company Lucida Medical
Subspeciality Abdomen
Modality MR
Disease targeted Prostate cancer
Key-features AI- supported prostate segmentation and volume, lesion segmentation, volumes and risk scores, PI-RADS v2.1 scoring support, structured report
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand), report suggestion,
Data characteristics
Population Prostate MRI scans with suspicion of prostate cancer, males >21 years
Input MRI, T2, DWI, DCE (optional)
Input format DICOM
Output Segmentation overlay, RTSTRUCT export for biopsy and 3D vizualization, structured report with key images, volumes and risk score
Output format DICOM
Integration Integration in standard reading environment (PACS)
Deployment Locally on dedicated hardware, Cloud-based
Trigger for analysis Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 1 - 10 minutes
Certified, Class IIb , MDR
No or not yet
Market presence
On market since 05-2021
Distribution channels Eureka Clinical AI
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing model Pay-per-use, Subscription
Based on Number of analyses, Number of installations
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers

  • Abstract: P9: AI for prostate MRI: results from a large multicentre, multi-vendor external validation study (read)